Table 1 Characteristics, functioning and anti-dementia drug use of patients by setting
Total | Residential care | Home care | P- value | |
|---|---|---|---|---|
(n = 2821) | (n = 1439) | (n = 1382) | ||
Characteristics | ||||
Female, n (%) | 1921 (68.1) | 995 (69.1) | 926 (67.0) | 0.223 |
Mean age, years (SD) | 80.9 (10.1) | 82.0 (9.8) | 79.8 (10.4) | <0.001 |
≤ 64, n (%) | 224 (8.0) | 89 (6.2) | 135 (10.6) | |
65-74, n (%) | 354 (12.6) | 172 (11.0) | 182 (12.5) | |
75-84, n (%) | 1056 (37.6) | 511 (35.6) | 545 (39.7) | |
≥ 85, n (%) | 1174 (41.8) | 664 (46.2) | 513 (37.2) | |
Diagnosis and functioning | ||||
Diagnosed dementia, n (%) | 1184 (43.8) | 774 (56.0) | 410 (31.1) | <0.001 |
ADL score (%, SD) | 58.4 (34.3) | 36.9 (30.8) | 80.8 (20.9) | <0.001 |
Bedridden, n (%) | 233 (8.3) | 221 (15.4) | 12 (0.9) | <0.001 |
Drug use | ||||
Total number of drugs, mean (SD) | 8.6 (4.7) | 8.5 (4.2) | 8.5 (5.3) | 0.437 |
Anti-dementia drug users, n (%) | 901 (31.9) | 516 (35.9) | 385 (27.9) | 0.007 |
AChEI alone, n (%) | 545 (19.3) | 262 (18.2) | 283 (20.5) | 0.015 |
Donepezil, n (%) | 291 (10.3) | 127 (8.8) | 161 (11.6) | |
Rivastigmine, n (%) | 153 (5.4) | 99 (6.9) | 54 (3.9) | |
Galantamine, n (%) | 107 (3.8) | 36 (2.5) | 69 (4.9) | |
Memantine alone, n (%) | 166 (5.8) | 125 (8.7) | 41 (3.0) | 0.003 |
AChEI and memantine | 190 (6.7) | 129 (9.0) | 61 (4.4) | <0.001 |
Donepezil + memantine, n (%) | 94 (3.3) | 60 (4.2) | 34 (2.5) | |
Rivastigmine + memantine, n (%) | 63 (2.2) | 51 (3.5) | 12 (0.9) | |
Galantamine + memantine, n (%) | 33 (1.2) | 18 (1.3) | 15 (1.1) |